%A Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang %T Treatment status of non-small cell lung cancer with METexon14 skipping mutation %0 Journal Article %D 2023 %J Journal of International Oncology %R 10.3760/cma.j.cn371439-20220930-00007 %P 37-41 %V 50 %N 1 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_11241.shtml} %8 2023-01-08 %X

MET exon14 （METex14） skipping mutation is an independent driver gene in non-small cell lung cancer （NSCLC）. About 3%-4% of NSCLC patients carry METex14 skipping mutation. These patients have poor prognoses and poor responses to traditional chemotherapy and immunotherapy. Highly selective MET inhibitors such as capmatinib， tepotinib， savolitinib have shown good efficacy and safety data in clinical trials， which bring new treatment options for patients with METex14 skipping mutations.